The Extracellular Matrix Component Psl Provides Fast-Acting Antibiotic Defense in Pseudomonas aeruginosa Biofilms by Ramirez Millan, Maria et al.
The Extracellular Matrix Component Psl Provides Fast-
Acting Antibiotic Defense in Pseudomonas aeruginosa
Biofilms
Nicole Billings1, Maria Ramirez Millan1,2, Marina Caldara1, Roberto Rusconi2, Yekaterina Tarasova1,
Roman Stocker2, Katharina Ribbeck1*
1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 2 Ralph M. Parsons Laboratory,
Department of Civil and Environmental Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
Abstract
Bacteria within biofilms secrete and surround themselves with an extracellular matrix, which serves as a first line of defense
against antibiotic attack. Polysaccharides constitute major elements of the biofilm matrix and are implied in surface
adhesion and biofilm organization, but their contributions to the resistance properties of biofilms remain largely elusive.
Using a combination of static and continuous-flow biofilm experiments we show that Psl, one major polysaccharide in the
Pseudomonas aeruginosa biofilm matrix, provides a generic first line of defense toward antibiotics with diverse biochemical
properties during the initial stages of biofilm development. Furthermore, we show with mixed-strain experiments that
antibiotic-sensitive ‘‘non-producing’’ cells lacking Psl can gain tolerance by integrating into Psl-containing biofilms.
However, non-producers dilute the protective capacity of the matrix and hence, excessive incorporation can result in the
collapse of resistance of the entire community. Our data also reveal that Psl mediated protection is extendible to E. coli and
S. aureus in co-culture biofilms. Together, our study shows that Psl represents a critical first bottleneck to the antibiotic
attack of a biofilm community early in biofilm development.
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Introduction
Hydrogels have broad applications in nature and form the basis
of vital selective barriers such as mucus, the tissue extracellular
matrix, and nuclear pores [1]. One important hydrogel barrier is
found in the extracellular matrix of bacterial biofilms [2–4]. The
biofilm matrix is secreted by, and surrounds, bacteria within a
biofilm. It confers adhesion to substrates and between the cells
[5,6], but it also serves as a selective filter, allowing the entry of
nutrients [2,7] while delaying passage of certain antimicrobials [8–
10]. The biofilm matrix is essential for bacterial defense against
environmental insults, yet the components and mechanisms that
govern its selectivity for small molecules, such as nutrients, toxins,
or antimicrobials, are still largely unknown.
The biofilm matrix is composed of diverse macromolecules
including proteins, extracellular DNA, and lipids. In addition, like
many other hydrogel barriers [11–15], the biofilm matrix contains
different types of polysaccharides. The biological function of
sugars outside metabolism is poorly understood: controlling the
filtration properties of hydrogels may be one of their central
functions. Indeed, alterations in polysaccharide composition and
concentration correlate with biofilm development. During initial
stages of biofilm formation, exopolysaccharides facilitate surface
and cell-to-cell attachment. As the biofilm matures, exopolysac-
charide production increases and diversifies, and contributes to the
generation of microcolony formation and more complex archi-
tecture [16]. Alterations in polysaccharide composition also
contribute to changes in biofilm antibiotic resistance [17,18].
Overall, the presence of a biofilm matrix, can lead to increased
resistance to antimicrobials and the host immune system simply
not observed in their free-swimming counterparts [2]. As a result,
biofilms can cause particularly devastating chronic infections or
facilitate life-threatening nosocomial infections in short time
courses [19–24]. A biofilm’s resilience to eradication can also
cause significant damage in environmental and industrial settings,
such as on ship hulls [25] and water pipeline systems [26].
Here, we investigate the role of individual polysaccharides on
the permeability of Pseudomonas aeruginosa biofilm matrix to
antibiotics. The gram-negative bacterium P. aeruginosa is an avid
biofilm former that is implicated in both chronic and acute
infections [27]. It represents an ideal model system to unravel the
barrier function of the biofilm matrix, because several components
of its matrix have been identified and partly characterized [18,28–
33]. In addition, clinical and environmental isolates with varying
compositions of exopolysaccharides are available, allowing a direct
comparison between extracellular defenses evolved in nature and
those formed by synthetically derived laboratory strains [34–38].
P. aeruginosa produces three major exopolysaccharides found within
the matrix: alginate, Pel, and Psl. In the laboratory strains WT
PAO1 and WT PA14, alginate is not a critical matrix component
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[28]. However, alginate overproduction is a characteristic of
mucoid clinical isolates found in the cystic fibrosis lung [39,40].
Alginate is comprised of blocks of b-1,4-linked d-mannuronic acid
residues and its 5-epimer l-guluronic acid [41,42]. Pel, a glucose
rich exopolysaccharide, is important for air-liquid interface pellicle
formation [31,32] and provides a structural scaffold during micro-
and macro-colony formation in WT PAO1 biofilms [18,43]. The
charge-neutral exopolysaccharide Psl is comprised of D-mannose,
D-glucose, and L-rhamnose arranged in pentasaccharide repeats
and provides structural support during biofilm formation, playing
a role in both cell to cell and cell to substrate attachment
[29,30,43].
To dissect the contributions of individual polysaccharides to
the matrix barrier at selected time points, we use antibiotic
tolerance as a reporter. Clinically relevant antibiotics with
different charges and mechanisms of action were selected for
this study. By comparing the efficacy of antibiotics against
biofilms formed by strains that lack different matrix components,
we can assess the importance of each polysaccharide in providing
tolerance to a specific antibiotic. We found in both static and
continuous-flow biofilm experiments, that genetic depletion of Psl
result in sensitization toward a range of antibiotics for young
biofilms, suggesting that Psl is a critical determinant for the
resistance properties of the biofilm matrix at initial developmental
stages. We also show that cells devoid of Psl (P. aeruginosa Dpsl, S.
aureus, and E. coli) can co-exist with Psl-containing biofilms and
effectively increase their tolerance. We speculate that Psl can
inhibit the function of a range of charged antibiotics by
sequestering them, and that removal of Psl in a clinical setting
would greatly enhance the efficacy of antibiotic treatments for
early onset infections.
Results and Discussion
To dissect the contribution of individual polysaccharides to the
matrix barrier function we first tested their role in tolerance
toward the antibiotic colistin, a critical last-resort antibiotic for
multidrug resistant P. aeruginosa [44,45]. Colistin belongs to the
family of polymyxin cationic antimicrobial peptides, which acts by
disrupting the cell membrane [44]. Since it is critical to address
infections at initial onset, particularly in burn and wound cases, we
examined the contribution of polysaccharide components at early
stages of biofilm development. [10,18]. One important part of our
protocol is to examine the killing effect of colistin upon short
exposure (2-hour). This exposure period is significantly shorter
than standard over-night and 24-hour treatments [18,46,47] and
approximates the time an antibiotic is available during a one-time
treatment before it is metabolized or digested [48]. This is in
contrast to other studies that analyze the roles of P. aeruginosa
exopolysaccharides toward antibiotic tolerance over longer expo-
sure times in more mature biofilms [10,18].
Using a microtiter plate assay [31,49], we determined the
minimal colistin concentration required to kill biofilms (the
minimal bactericidal concentration for biofilms, MBC-B) formed
by wild type PAO1 (WT). Experiments were repeated for strains
lacking expression of either of the three identified P. aeruginosa
exopolysaccharides, alginate (DalgD), pel (DpelA), and psl (DpslAB).
Fig. 1A shows that 63 mg/ml colistin were needed to eradicate WT
PAO1 biofilms, whereas only 15 mg/ml were required to eradicate
biofilms lacking Psl, which was more than a four-fold decrease in
MBC-B in the absence of Psl. In contrast, the MBC-B for alginate-
free biofilms (DalgD) and Pel-free biofilms (Dpel) were not
significantly different from the MBC-B for the wild type. This
suggests that Psl, but not Pel or alginate, can form a first line of
defense against colistin for short-term antibiotic for 24-hour
biofilms. Colistin sensitivity was not altered for cells lacking a
functional algD gene product. This result is somewhat expected
because alginate is not abundantly expressed in WT PAO1 in vitro
laboratory models early in biofilm development [28]. We are
therefore cautious in the interpretation of this result. The lack of
Pel was previously shown to sensitize 24 to 48-hour biofilms to
aminoglycosides in the laboratory strain PA14, but not for WT
PAO1, consistent with the results presented here [18]. In parallel
to the MBC-B assay, which reveals the concentration required to
eradicate all cells in biofilm, we also determined the reduction in
viable colony forming units (CFUs) before and after exposure to a
fixed concentration of antibiotic. Biofilms were exposed to 32 mg/
ml colistin for two hours (Figure S1A) and viable CFUs were
quantified on agar plates. At this concentration of colistin, DpslAB
cells were eradicated, whereas WT PAO1, DalgD, and DpelA
biofilms were able to persist. This line of experiments confirmed
our conclusion that Psl can mediate protection against colistin for
24-hour biofilms.
To examine the contribution of each polysaccharide also in
more mature biofilms, we assayed the sensitivity to colistin of
biofilms that had grown for 48 and 72 hours. These results show
that Psl exerts a protective effect for 24-hour old biofilms, but did
not greatly influence biofilm susceptibility after 48 and 72 hours of
maturation (Figure S1A). Additionally, these data show that
neither alg nor pel are critical for biofilm tolerance toward colistin
at any time point of development tested here (Figure S1A).
DpslAB cells form biofilms more slowly than wild type cells
[30,50] and have a reduced total biomass compared to WT PAO1
(Figure 2A, S3). Hence, to address the possibility that increased
colistin sensitivity for DpslAB biofilms was caused by lower cell
numbers, rather than an altered matrix composition, we deter-
mined the MBC-B for WT and DpslAB biofilms at multiple time
points during early biofilm development. Figure 2B illustrates that
the MBC-Bs after 2-hour colistin exposure were independent of
biofilm age and, for WT, remained constant for 6, 12, 18 and 24-
hour biofilms. Together these results suggest that the increased
sensitivity to colistin of the DpslAB biofilms was not due to fewer
cells present in the biofilm, but, rather, to the lack of Psl in the
biofilm matrix, which in turn appears to affect the interaction of
the antibiotic with the cells.
Author Summary
Many bacteria have the ability to form multicellular
communities, termed biofilms. An important characteristic
of a biofilm is the ability of cells to synthesize and secrete
an extracellular matrix. This matrix offers structural
support, community organization, and added protection,
often making the cells impervious to desiccation, preda-
tion, and antimicrobials. In this study, we investigate the
contributions of polysaccharide components found in the
extracellular matrix of Pseudomonas aeruginosa at pro-
gressive stages in biofilm development. We first show that
one specific polysaccharide, Psl, provides an added
defense for P. aeruginosa biofilms against antimicrobials
of different properties for young biofilms. Then, by
cultivating biofilms that contain both Psl producing and
Psl non-producing strains, we find that P. aeruginosa, E.
coli, and S. aureus species that lack Psl take advantage of
the protection offered by cells producing Psl. Collectively,
the data indicate that Psl is likely to play a key protective
role in early development of P. aeruginosa biofilm
associated infections.
Psl Provides Defense for P. aeruginosa Biofilms
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To determine if Psl tolerance against colistin is effective only if
cells are within a biofilm, we examined the minimal inhibitory
concentration (MIC) of colistin for WT and DpslAB stationary
phase planktonic cells normalized to the same cell density. Even in
the planktonic state, Psl is constitutively expressed and localizes to
the cell surface in WT PAO1 [51]. We found a 4-fold reduction in
tolerance to colistin for planktonic DpslAB (Table 1). Although this
shift in sensitivity is not as pronounced as in the biofilm state, this
data suggests that Psl may contribute to protection for planktonic
cells, even in the absence of any protective structure and changes
in cellular physiology that arise from the biofilm. Differences in
MIC relative to WT PAO1 were not observed for planktonic
DalgD or DpelA (Table 1).
Is the barrier effect of Psl specific to colistin or does it extend to
other clinically relevant antibiotics? To address this question we
tested if the loss of Psl would also affect sensitivity toward another
cationic antimicrobial peptide, polymyxin B. In addition, we tested
sensitivity toward the aminoglycoside tobramycin, a vital first-
round treatment of Pseudomonal associated infections [52,53],
and the fluoroquinolone ciprofloxacin, an antibiotic used com-
monly in P. aeruginosa infections due to the ease of oral dosing and
limited toxicity. As with colistin, we observed an increase in
sensitivity (as determined by the MBC-B) of DpslAB biofilms
relative to WT biofilms for polymyxin B (Figure 1B 32 mg/ml WT
PAO1, 16 mg/ml DpslAB), tobramycin (Figure 1C; 785 mg/ml WT
PAO1, 285 mg/ml DpslAB), and ciprofloxacin (Figure 1D; 90 mg/
ml WT PAO1, 54 mg/ml DpslAB). The antibiotic sensitivity was
also tested for each antibiotic at different times of biofilm
development (24, 48, and 72 hours). As observed before, Psl-
mediated protection was critical earlier in biofilm development
(24 hours), but dispensable at later time points (S1B; S2A,B). Of
note is that Dpel and DalgD biofilms did not show an altered
antibiotic sensitivity compared to WT biofilms at 24 hours.
However, Dpel biofilms show a modest decrease in viability at
48 hours when treated with tobramycin or colistin, and also at
72 hours when treated with tobramycin. Together, these results
suggest that Psl not only protects cells from colistin, but also can
suppress the function of additional antibiotics at initial stages of
biofilm development.
If a deletion of Psl renders biofilms more sensitive to the
antibiotics tested here, then we would expect that elevated levels of
Psl have the opposite effect and increase antibiotic tolerance. To
test this we used a strain derived from WT PAO1 where the native
psl promoter was replaced with an arabinose-inducible promoter
(PBAD-psl). We found that colistin tolerance directly correlates with
the levels of Psl produced, rising from an MBC-B of 24 mg/ml to
125 mg/ml in dependence of the level of Psl overexpression
(Figure 3A, B). This result was confirmed for colistin, polymyxin B,
and tobramycin with antibiotic sensitivity assays (S1A, B; S2A) at
24 hours.
We also compared the tolerance of the synthetically derived
DpslAB to a strain that naturally lacks Psl (PA14). PA14 does not
produce Psl owing to a 3-gene deletion in the psl operon [32]. The
lack of Psl in the PA14 matrix was confirmed by staining of the
biofilms with fluorescently labeled HHA lectin, which binds to Psl
[54] (Figure S4). 24-hour PA14 biofilms were with a MBC-B of
24 mg/ml similarly sensitive to colistin as DpslAB (Figure 3A). This
result was supported with viability counts for cells exposed to
colistin and polymyxin B (Figure S1A, B). Notably, more mature
PA14 biofilms at 48 and 72 hours had developed an increased
tolerance to colistin and polymyxin B, similar to DpslAB at these
later time points (Figure S1A, B). However, in contrast to DpslAB
biofilms, PA14 biofilms at 24 hours were more tolerant to the
aminoglycoside tobramycin. This is in agreement with a previous
report, which demonstrated that the Pel rich matrix of PA14
provides protection against aminoglycoside antibiotics [18].
In the converse experiment we measured colistin tolerance of
CF127, a natural isolate that secretes increased levels of Psl
Figure 1. The exopolysaccharide Psl promotes P. aeruginosa biofilm tolerance to both cationic and anionic antibiotics. Results of the
MBC-B assay reveal that removal of Psl increases sensitivity to positively charged colistin (A) and tobramycin (B) and polymyxin B (C). In addition,
removal of Psl sensitizes biofilms to negatively charged ciprofloxacin (D). (*) indicates statistical significance from WT PAO1 as determined by a
student’s t-test (P,0.05). Error bars represent SEM (n=3).
doi:10.1371/journal.ppat.1003526.g001
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compared to WT PAO1 [38]. The CF127 biofilm grows in distinct
microcolonies (Figure S4), and staining with HHA lectin [54]
showed that Psl localizes to the CF127 microcolonies (Figure S4).
The MBC-B of CF127 toward colistin was 125 mg/ml and hence,
comparable to that of the overproducing PBAD-psl strain
(Figure 3A). Interestingly, the increased colistin tolerance of
CF127 compared to WT PAO1 was not apparent in viability
counts (Figure S1A,B; S2A,B). We speculate that structural
differences of CF127 biofilms may result in antibiotic tolerance
to a sub-population of cells within these structures, which are not
resolved in the viability assay.
To obtain mechanistic insight into Psl mediated protection, we
considered the possibility that Psl may directly sequester antibiotics
to the matrix and thereby limit its access to the cell surface. We
compared WT PAO1, PA14, DpslAB, PBAD-psl, and CF127
biofilms subjected to 5 mg/ml fluorescent polymyxin B after
2 hours of exposure. In the presence of PBAD-psl cells the antibiotic
distributed along a fibrous matrix heterogeneously throughout the
biofilm matrix, and also associated with matrix material in
planktonic culture (Figure 4 and S5). The fibrous material was less
pronounced for WT PAO1, where the localization of polymyxin B
was distributed diffusely within the biofilm (Figure 4). This
distribution of matrix associated polymyxin B was not observed
with the Psl deficient DpslAB strain or PA14. (Figure 4 and S5).
Here, fluorescence was detected in close vicinity of the cell
periphery, suggesting that polymyxin B may be interacting with
the cell membrane. Of note, polymyxin B localized to the
periphery of CF127 microcolonies, but was not observed within
the structure.
The binding of fluorescent polymyxin B to the biofilm matrix
may, in part, result from electrostatic interactions with the matrix
components. To probe for such interactions, we performed
antibiotic sensitivity assays at varying ionic strengths through the
addition of NaCl to the challenge medium (Figure 5). In growth
medium or buffer, charged polymers interact with dissolved ions,
which to some extent, form a shell of opposite charges around the
molecules. This screening of electrostatic interactions becomes
more pronounced with increasing salt concentrations and as a
result, the ionic strength in the system will influence the interaction
between matrix polymers and diffusing molecules. Specifically, if
electrostatic interactions occur between the Psl matrix and the
antibiotic molecules, an increase in NaCl concentration may affect
these interactions. The challenge medium with 32 mg/ml colistin
and no further addition of NaCl reduced the amount of viable cells
in a 24-hour WT PAO1 biofilm by nearly one half of the total
population. However, in the presence of a challenge medium that
contained 32 mg/ml colistin and 50 mM NaCl, the total biofilm
population was eradicated (Figure 5A). Similar effects were
observed for positively charged antibiotics polymyxin B, and
tobramycin with a higher concentration of NaCl (250 mM;
Figure 5B–C), but not for the negatively charged ciprofloxacin
(Figure 5D). We conclude that electrostatic interactions may partly
contribute to the sequestration of the antibiotics by the Psl matrix,
and that high ionic strength can suppress these interactions,
potentially leading to an increased efficacy of the antibiotics. We
note that Psl itself is neutrally charged [29], hence, it is conceivable
that Psl functions when complexed to other matrix components
that could provide the negative charge.
In many environments biofilms grow under flow conditions and
these may affect the biofilms’ barrier properties. To address the
role of flow on our findings, we assessed antibiotic susceptibility to
colistin in a flow-through microfluidic device. The killing dynamics
were examined as biofilms were exposed to 20 mg/ml colistin or
buffer without antibiotic for 2 hours (Figure 6; S6). In WT
biofilms, .80% of the cells survived a 2-hr exposure to the
antibiotic (Figure 6 A,B). In contrast, ,20% of DpslAB cells
survived, providing further support for our findings and demon-
strating that the barrier effect was not compromised by flow and
hydrodynamic shear (Figure 6B), although some biomass loss was
observed (7% loss for WT PAO1 and 12% loss for DpslAB; Figure
S7). Moreover, a biofilm that over-produces Psl (PBAD-psl) again
Figure 2. Psl protection is independent of biofilm age up to
24 hours. (A) Cell number count for WT PAO1 and DpslAB at 6, 12, 18,
and 24 hours in biofilm development (B) The MBC-B of WT PAO1 and
DpslAB at 6, 12, 18, and 24 hours suggest that sensitivity to antibiotics
was the result of modulating the matrix and not a consequence of cell
number in immature biofilms. Error bars represent SEM (n=3).
doi:10.1371/journal.ppat.1003526.g002
Table 1. The minimal inhibitory concentration (MIC) of
colistin for stationary phase cells normalized to equal cell
density, and the minimum bactericidal concentration of
colistin for biofilms (MBC-B) after a 2 hour exposure.
Strain MIC (colistin mg/ml) MBC-B (colistin mg/ml)
PAO1 12 63
PA14 12 24
DpslAB 3 15
DalgD 12 63
DpelA 12 78
PBAD-psl 12 125
PBAD-psl (un-induced) 6 24
CF127 12 125
doi:10.1371/journal.ppat.1003526.t001
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shows increased tolerance against colistin compared to a WT
biofilm (Figure 6B).
Psl is an extracellular product potentially accessible to foreign
cells that are natively devoid of this polymer and hence are, by
themselves, more sensitive to antibiotic attack. If non-producing
cells are able to coexist with the Psl producers they may be able to
exploit the protection by Psl and gain tolerance. This scenario
could be relevant in natural settings, where biofilms are often not
limited to a single strain or species [55,56]. We first determined
whether DpslAB cells and the Psl overproducing PBAD-psl cells
could form co-strain biofilms. For this experiment we expressed
the fluorescent protein mCherry in DpslAB cells, mixed them with
PBAD-psl cells to form a co-strain biofilm. Figure 7A shows that
DpslAB cells (red) can indeed grow inside a ‘‘Psl donor’’ biofilm,
even if they were incorporated less effectively than the PBAD-psl
cells and therefore represent a smaller proportion of the biofilm.
One reason for this is the delay of the DpslAB cells to attach and
mature into biofilms due to their lack of Psl [30] (Figure S3).
The presence of non-producers was not without effect for the
entire biofilm, as it weakened the biofilm’s tolerance capacity
(Figure 7B). We inoculated biofilms with different ratios of DpslAB
and PBAD-psl cells, and measured the MBC-B for each emerging
biofilm. Figure 7B shows that the sensitivity of the composite
biofilm toward colistin increased in proportion to the amount of
DpslAB cells present in the initial inoculum. This result suggests
that the inclusion of non-producers can reduce the tolerance of the
entire biofilm, and that a critical amount of exopolysaccharides
per cell is needed for effective protection.
While compromising the overall protective effect from Psl over-
producers by becoming part of their biofilm, DpslAB cells could
benefit from the access to the protective exopolysaccharides. We
tested if DpslAB cells within a PBAD-psl biofilm would survive higher
concentrations of colistin than their counterparts growing in a
monoculture. Within a monoculture, DpslAB biofilms could
survive colistin concentrations at 4 mg/ml (Figure 7C). In contrast,
as part of a joint biofilm with Psl donors, DpslAB cells were able to
survive colistin concentrations up to 32 mg/ml, which would
normally kill them (Figure 7C). How many DpslAB cells the biofilm
was able to host without reducing the effective Psl-mediated
protection depended on the intensity of the antibiotic attack. By
scanning a range of antibiotic concentrations and counting the
number of DpslAB cells that survived treatment, we found that at
an antibiotic concentration of 8 mg/ml the biofilm contained 13%
DpslAB cells, while at 32 mg/ml concentration this fraction
dropped to 3% (Figure 7C). Thus, DpslAB cells can benefit from
interacting with PBAD-psl cells, even if at the expense of the
performance of the Psl-donors. This implies that certain species
that lack protective capacity may become more tolerant to therapy
as part of mixed-species biofilms.
Biofilms associated with infections are frequently co-populated
by multiple species [57–60]. Hence, one important question is if
Psl can affect the viability of species that coexist within Pseudomonas
biofilms. Both gram-negative E. coli and gram-positive Staphylococ-
cus aureus colonize wounds [61–64] and are hence good candidates
to address this question. First, we tested if E. coli and S. aureus form
mixed species biofilms when co-cultured with PBAD-psl and
DpslAB, respectively (Figure 8A, B, E, F). E. coli readily formed
biofilms at the air-liquid interface (Figure 8E) as a monoculture
and when co-cultured with P. aeruginosa. S. aureus formed biofilms at
the bottom of a 96 well plate in the absence of P. aeruginosa.
However, when co-cultured with P. aeruginosa, S. aureus was
incorporated into the air-liquid interface biofilm.
To determine if Psl could provide any advantage for E. coli, we
quantified E. coli sensitivity to 32 mg/ml colistin in the presence
and absence of Psl-producing cells. As a monospecies biofilm or
when incorporated in a DpslAB biofilm, E. coli was eradicated by
this concentration of colistin (Figure 8C). However, when grown
together with the PBAD-psl, E.coli viability was only mildly
compromised by the same treatment (Figure 8C), suggesting that
E. coli can benefit from the protective effects of Pseudomonas-derived
Psl. Supporting this result was the MBC-B assay, which shows that
the presence of PBAD-psl enhanced tolerance of E. coli to 104 mg/
ml of colistin (Figure S8A). A similar conclusion might be drawn
for S. aureus: the monoculture was eradicated with 1 mg/ml of
tobramycin and substantially decreased with 0.5 mg/ml, but the
cells survived even 1 mg/ml of tobramycin when co-cultured with
Pseudomonas (Figures 8D). When assessing viable CFUs (Fig. 8D),
the protection from the Psl overproducing PBAD-psl strain was only
slightly higher compared to the protection from the DpslAB strain.
However, the difference becomes clearer in the MBC-B data
Figure 3. Over-expression of psl increases biofilm tolerance to
colistin. Opposite to DpslAB, Psl over-producing strain PBAD-psl shows
increased tolerance to colistin. (A) Strains that naturally lack (PA14) and
over-express Psl (CF127) have similar sensitivities as the synthetic
DpslAB and PBAD-psl, respectively. (B) Since Psl production was directly
controllable in the over-producing strain by modulating the amount of
the inducer (arabinose) in the culture medium, we could determine if
tolerance correlated to the levels of Psl in the biofilm matrix. Biofilms
that were formed in the presence of glucose tightly inhibited the
expression of PBAD-psl, which resulted in increased sensitivity to colistin
similar to DpslAB. For the data presented, shades of blue represent
strains that do not produce Psl while shades of red represent strains
that over-produce Psl. (*) indicates a significantly lower bactericidal
antibiotic concentration and (**) indicates a significantly higher
bactericidal antibiotic concentration when compared to WT PAO1 as
determined by a student’s t-test (P,0.05). Error bars represent SEM
(n=3).
doi:10.1371/journal.ppat.1003526.g003
Psl Provides Defense for P. aeruginosa Biofilms
PLOS Pathogens | www.plospathogens.org 5 August 2013 | Volume 9 | Issue 8 | e1003526
Figure 4. Polymyxin B interacts with the Psl extracellular matrix. Images ofWT PAO1, PA14, DpslAB, PBAD-psl, and CF127 biofilms subjected to
5 mg/ml fluorescent polymyxin B after 2 hours of exposure. Polymyxin B accumulates in the extracellular material of PBAD-psl and is less pronounced
in WT PAO1 biofilms. Fluorescent Polymyxin B did not localize to the matrix in PA14 or DpslAB biofilms, but instead closely associated with the cell
surface. For CF127, Polymyxin B was distributed around the periphery of microcolonies within the biofilm. Scale bars represent 10 mm.
doi:10.1371/journal.ppat.1003526.g004
Figure 5. Ionic strength of the challenge medium influences biofilm susceptibility to positively charged antibiotics. Bacterial survival
was assessed for WT PAO1, PA14, DpslAB, and PBAD-psl after exposure to colistin (A), polymyxin B (B), tobramycin (C), and ciprofloxacin (D) in the
presence or without NaCl. By increasing the ionic strength of the challenge medium with NaCl, electrostatic interactions are predicted to be reduced,
leading to an increased efficacy of the positively charged antibiotics colistin, polymyxin B, and tobramycin, but not of ciprofloxacin. Error bars
represent SD (n= 3).
doi:10.1371/journal.ppat.1003526.g005
Psl Provides Defense for P. aeruginosa Biofilms
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(Figure S8B), which shows that S. aureus can tolerate a higher
concentration of tobramycin in PBAD-psl biofilms than in DpslAB
biofilms, or as monoculture (Figure S8B).
The extracellular matrix in biofilms has long been implicated as
a barrier for protection [65], but its exact contribution to
resistance is not clear. One reason for this is that the bulk of
methods to measure resistance are based on the exposure of cells
to antibiotics over long time scales (over-night to 48 hours)
[10,18,46]. This allows for many cell divisions to occur, giving the
cells time to build adaptive mechanisms at the cellular or genetic
level. However, these studies may mask any contribution from a
physical barrier, which should be apparent at much shorter time
scales: if the matrix acts as a true physical shield then matrix-
embedded bacteria should show immediate tolerance on exposure
to antibiotics.
To focus on the physical barrier effects of the matrix we tested
the short-term tolerance response of bacteria, and the contribution
of the known matrix polysaccharides within. We found that Psl can
provide instant defense and contributes to protecting cells from the
action of a broad spectrum of antibiotics with diverse biochemical
properties. Psl provides a measure of protection from cationic
antimicrobial peptides (colistin, polymyxin B), tobramycin, and to
some extent ciprofloxacin. Importantly, this protection is observed
in early stages of biofilm development but does not have a
profound effect at later time points (48, 72 hour biofilms). As the
biofilm continues to develop into the characteristic mushroom
shaped microcolonies [18,30,43] resulting in spatio-temporial
changes in the matrix [43,51], we conclude that different barrier
properties arise from the biofilm structure and other polymers
which may be redundant to, or dominate over, Psl function.
Supporting our data on the protective effect of Psl is a recent
report that shows that strains producing Psl are capable of growth
and biofilm formation in the presence of the anti-biofilm agent
Polysorbate 80, a non-ionic surfactant [50]. Psl is found in two
forms in the matrix, where large molecular weight oligosaccharide
repeats localize around the cell surface [30] and smaller, soluble
fractions are distributed throughout the matrix [29]. Based on the
localization results of fluorescent polymyxin B, it is possible that
the polymer attracts the small antibiotic molecules by direct
interaction, as has been proposed for alginate [66,67] and ndvB-
Figure 6. Psl contributes to colistin tolerance for biofilms
grown under flow. Colistin kill kinetics for 18-hour old biofilms WT
PAO1, Psl deficient, and over-producing Psl strains. The Psl deficient
strain was substantially more susceptible to colistin compared to the
wild type, whereas over-producing Psl was less sensitive. Error bars
represent SD (n= 3).
doi:10.1371/journal.ppat.1003526.g006
Figure 7. Psl producing cells offer a protective advantage to Psl deficient cells. Mixed PBAD-psl and DpslAB (red cells) biofilm population
before and after (A) treatment with colistin, cells in the biofilm were removed from the 96 well plate and imaged. (B) MBC-B results for mixed culture
biofilms reveal that the presence of DpslAB sensitized the PBAD-psl to lower concentrations of colistin. (C) A monoculture of DpslAB survived exposure
to 4 mg/ml of colistin without the requirement of Psl in the matrix. DpslAB can survive increasing concentrations when part of a joint biofilm with
PBAD-psl, up to 32 mg/ml. Error bars represent SEM (n= 3). Scale bars represent 10 mm.
doi:10.1371/journal.ppat.1003526.g007
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encoded periplasmic glucans [10,68] or reduces affinity of antibiotics
to the cell surface. In support of an interaction mechanism, we also
show that this attraction may be attributed to, in part, by electrostatic
interactions between the antibiotics and the biofilm matrix since the
addition of NaCl sensitizes cells with a Psl rich matrix to positively
charged antibiotics. Further, the presence of Psl could contribute to
indirect effects on antibiotic tolerance such as limiting the diffusion of
oxygen or other nutrients, contributing to a more dormant cellular
state. However, it is important to note that we did not detect a
difference in growth rate for any of the strains. Nevertheless,
deciphering the barrier mechanism of Psl may inspire solutions to
some vexing treatment challenges in medicine at the initial stages of
biofilm associated infections in burns and wounds, where early
treatment for bacterial eradication is imperative.
An external barrier as the sole defense mechanism is probably
risky, as its capacity to sequester molecules is likely limited.
However, such a fast-acting physical barrier may offer cells enough
time to build up synergistic and longer-term defense systems. The
presence of a physical barrier also implies that it is potentially
accessible to more sensitive bacterial species that would otherwise
succumb to antibiotic exposure. Our in vitro system highlights the
possibility that interaction with a protective matrix can render a
sensitive strain resistant. Importantly, we observed that Psl
mediated protection is extendable to E. coli and S. aureus which
also readily colonize burns and wounds. These results may explain
why, in many cases, mixed species biofilms are more tolerant to
therapy than their monoculture counterparts [69–72]. However,
the opposite perspective, where co-habitation of a matrix deficient
strain compromises the tolerance properties of the biofilm
community as a whole, is also important. From a biochemical
standpoint this implies that a certain polymer-to-cell ratio is
optimal for protection, and that the polymers can become depleted
by excessive amounts of non-producers. From a therapeutic
outlook, the depletion of the protective polymers may be
considered in future treatment strategies of initial onset infections.
Materials and Methods
Strains, culture conditions, and antibiotics
The Pseudomonas aeruginosa strains used in this study are as
follows: laboratory wild type PAO1, laboratory wild type strain
PA14, PAO1DpslAB (Psl deficient), and PAO1-PBADpsl (over-
producing Psl), PAO1DalgD, PAO1DpelA, and cystic fibrosis isolate
CF127. The mutant strains PAO1DpslAB, PAO1-PBADpsl, and
PAO1DalgD were a generous gift of Daniel J. Wozniak. PAO1Dpel
and cystic fibrosis isolate CF127 were a generous gift of Matthew
R. Parsek. Other strains include E. coli EMG2 constitutively
expressing GFP from pBBR1(MCS5)-Plac-gfp and Staphylococcus
aureus UAMS-1 and were used for co-culture experiments. Details
and references for all strains can be found in Text S1. All of the P.
Figure 8. Psl provides a protective advantage for E. coli and S. aureus. Both E. coli (A, E) and S. aureus (B, F) form mixed species biofilms with
DpslAB and PBAD-psl. E. coli did not require the presence of P. aeruginosa to form a biofilm at the liquid-air interface on polystyrene (E); however, S.
aureus formed a biofilm at the liquid-air interface only in the presence of P. aeruginosa (F). Psl-mediated protection was extendable to E. coli biofilms
co-cultured with PBAD-psl. The addition of 32 mg/ml of colistin eradicated monospecies and DpslAB E. coli mixed species biofilms; however, E. coli cells
co-cultured with PBAD-psl were protected (C). Similar effects were observed for S. aureus, although a protective effect was also observed with DpslAB
cells (D). E. coli cells were identified via expression of GFP while P. aeruginosa cells were non-fluorescent (E). S. aureus cells were identified with
hexidium iodide (red) where as P. aeruginosa cells were stained with Syto 9 (green) (F). Scale bars represent 5 mm (E) and 10 mm (F).
doi:10.1371/journal.ppat.1003526.g008
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aeruginosa strains and E. coli EMG2 were cultured in 1% Tryptone
Broth (TB). S. aureus was cultured in LB broth for both
monoculture and co-culture experiments. Selective agar plates
were used to evaluate CFU counts for P. aeruginosa (Cetrimide
Agar; Sigma-Aldrich 70887) and S. aureus (Mannitol Salt Phenol
Red Agar; Sigma-Aldrich 63567) co-culture biofilms. Arabinose
was maintained culture medium of PAO1-PBADpsl and in all co-
strain/species biofilm experiments at a final concentration of 2%
unless otherwise noted. As a control, arabinose was added to the
culture medium of WT PAO1 to confirm that arabinose did not
influence biomass or antibiotic resistance for each. The strain
PAO1DpslAB (Psl deficient) was transformed with pMP7605-
mCherry [73] (the plasmid construct pMP7605-mCherry was
kindly provided by Ellen L. Lagendijk, Institute of Biology, Leiden
University, The Netherlands) via standard methods in bacterial
conjugation [74]. For P. aeruginosa and E. coli strains cultures, an
OD600 of 0.0025 represents a culture density of ,5.06105 and for
S. aureus an OD600 of 0.0025 represents a culture density of
,5.06104.
Antibiotics from three classes that target P. aeruginosa were
chosen for investigation (Text S1): polymyxins (colistin sulfate salt
Sigma-Aldrich #C4461; polymyxin B sulfate Sigma-Aldrich
#P0972), aminoglycosides (Tobramycin Sigma-Aldrich
#T4014), fluoroquinolones (Ciprofloxacin Sigma-Aldrich
#17850). They were chosen due to their clinical relevance,
difference in net charge, and difference in mechanism of action.
Microtiter biomass assay
The total biofilm biomass for each of the P. aeruginosa strains
used in this study was quantified with crystal violet staining as
previously described [75]. Briefly, biofilms were grown in 96 well
polystyrene microtiter plates in 1% TB medium at room
temperature for 24, 48 and 72 hours (150 ml of culture diluted
to an OD600 0.0025 per well). For 48- and 72-hour biofilms, the
medium was aspirated and replaced with fresh 1% TB each day
(supplemented with 2% arabinose). At the end of each time point,
the medium was aspirated and the plates were washed twice with
tap water to remove any planktonic cells. 175 ml of 0.1% crystal
violet was added to each well and remained for 10 minutes at
room temperature. After staining, the crystal violet solution was
aspirated and the plates were washed twice with tap water to
remove any residual stain. The plates were allowed to dry for at
least 30 minutes, followed by solubilization of the stained biofilm
with 175 ml of 33% acetic acid. The resulting absorbance was
recorded at 550 nm.
Lectin staining
HHA-TRITC (EY Labs) was used at a final concentration of
200 mg/ml as previously described [54]. Biofilms were grown at
the air-liquid interface on UV sterilized polystyrene surfaces for
24 hours. The biofilms were submerged in the lectin solution for
30 minutes and imaged with a Zeiss LSM 510 Meta Confocal
using a 1006/1.4 NA oil immersion objective.
Minimal Inhibitory Concentration (MIC) assay for
stationary phase cells
The MIC was determined by a standard micro-dilution protocol
with modifications. Cells grown to stationary phase were
normalized to an OD600 0.5 and were exposed to 2-fold series
of colistin dilutions in order to determine the minimal concentra-
tion of colistin that reduced cell viability within two hours. After
the challenge, the planktonic cells were centrifuged at 6000 rpm
and washed with PBS to remove residual antibiotic. The cultures
for each dilution were plated on LB agar plates without antibiotics
to determine the minimum concentration of colistin required to
inhibit growth within the two hour time frame.
Minimal Bactericidal Concentration for Biofilms (MBC-B)
This assay was performed as described previously [49] with
modifications. Briefly, mid-exponential phase cultures were
normalized to an OD600 0.0025 in 1%TB. 150 ml of diluted
culture was added to each well of a polystyrene 96-well microtiter
plate and incubated for 24 hours at room temperature. The
medium in each well was aspirated to remove planktonic cells. The
resulting biofilms were carefully washed with PBS (pH 7.4) to
remove any remaining unattached cells. Two-fold dilutions of
antibiotics tested were prepared in appropriate solvents and 150 ml
of the antibiotic dilutions were added to the biofilm plate (0–
1 mg/ml for colistin, 0–1 mg/ml for polymyxin B, 0–10 mg/ml
for tobramycin, and 0–1 mg/ml ciprofloxacin). After 2 hours, the
antibiotic was removed and the biofilms were carefully rinsed with
PBS. 150 ml of PBS was added to each well along with 150 ml of
sterile glass beads (Sigma-Aldrich #G8772; 425–600 mm). The
plate was covered with sterile aluminum sealing film (Sigma-
Aldrich #Z722642) to prevent any cross-contamination between
wells. The plate was then vortexed for 5 minutes to remove
adherent cells from the polystyrene well. To quantify cell viability,
35 ml per well was plated on LB agar without antibiotics. The
lowest antibiotic concentration that inhibited growth was consid-
ered to be the minimal bactericidal concentration for the biofilm
(MBC-B).
For mixed culture MBC-B analysis, mid-exponential phase
cultures were inoculated at different ratios, but the total cell
number in solution remained constant when added to each well.
To quantify the percentage of Psl deficient survivors after
antibiotic challenge, DpslAB expressing fluorescent mCherry were
quantified with phase contrast and fluorescence microscopy using
a Zeiss Observer Z.1 epifluorescent microscope with a 406/0.75
NA dry objective. The percent survival of Psl deficient cells was
calculated by determining the number of fluorescent cells relative
to the total cell population.
Antibiotic sensitivity assays
The antibiotic sensitivities of air-liquid interface biofilms on
polystyrene 96 well microtiter plates were assessed at 24, 48, and
72 hours. The microtiter wells were inoculated with 150 ml of
culture at an OD600 of 0.0025. For 48- and 72-hour biofilms, the
medium was aspirated and replaced with fresh 1%TB each day.
For each time point, the medium was aspirated from the well and
gently washed with PBS to removed non-adherent cells. Biofilms
were exposed to 32 mg/ml colistin, 32 mg/ml polymyxin B,
650 mg/ml tobramycin, or 50 mg/ml ciprofloxacin for 2 hours.
Cells were removed by the glass bead method described above for
MBC-B assays. Viability was quantified by serial dilutions and
CFU counts of the surviving population.
To evaluate the contribution of electrostatic interactions
between matrix components and antibiotics, the antibiotic
sensitivity was determined for colistin, polymyxin B, tobramycin,
and ciprofloxacin with the addition of 50 mM NaCl. 250 mM
NaCl was also evaluated for tobramycin. The effect of NaCl on
bacterial attachment was quantified by adding the appropriate
concentration of NaCl to the challenge medium without antibiotic.
Viability was quantified by serial dilutions and CFU counts of the
surviving population.
For determining cell viability of the P. aeruginosa mixed culture
air-liquid interface biofilms with E. coli and S. aureus, cultures were
inoculated at a 1:1 ratio. An independent evaluation (CFU counts)
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of the biofilm population was conducted for each mixed species
biofilm to quantify the composition of cells inhabiting the biofilm
before antibiotic treatment. For P. aeruginosa and E. coli mixed
biofilms, the ratio of colonies expressing GFP (E. coli strain)
compared to non-fluorescent cells (P. aeruginosa) was determined
after plating CFUs. For P. aeruginosa and S. aureus mixed biofilms,
CFU counts for each species were assessed with selective media for
each strain.
Imaging mixed species biofilms
E. coli expressing GFP and P. aeruginosa strains were inoculated
at a 1:1 ratio (or as monocultures) and grown at the air-liquid
interface on UV sterilized polystyrene surfaces for 24 hours.
Fluorescence and phase contrast images were acquired to
determine the biofilm forming capabilities of E. coli at the air-
liquid interface on a polystyrene surface both with and without P.
aeruginosa. A similar procedure was performed for S. aureus. To
determine the biofilm forming capabilities of S. aureus at the air-
liquid interface on a polystyrene surface both with and without P.
aeruginosa, S. aureus was stained with the gram-positive specific dye,
hexidium iodide (Molecular Probes). P. aeruginosa was identified
with Syto 9 staining (Molecular Probes).
Polymyxin B binding assays
Fluorescently labeled Polymyxin B (green-fluorescent BODIPY
FL-Polymyxin B; Molecular Probes, Invitrogen) was used at a final
concentration of 5 mg/ml. Stationary phase cultures were chal-
lenged with 5 mg/ml of Bodipy-polymyxin B for 2 hours. An
aliquot of each culture was immobilized on a 1% agarose covered
glass slide. Air-liquid interface biofilms grown on UV sterilized
polystyrene squares were treated with 5 mg/ml Bodipy-polymyxin
B for 2 hours. All images for Bodipy-polymyxin B assays were
acquired with a Zeiss LSM 510 Meta Confocal using a 1006/1.4
NA oil immersion objective.
Microfluidic-based time-kill kinetic assay
A PDMS (Polydimethylsiloxane; Sylgard 184; Dow Corning,
MI, USA) microfluidic device was molded from a silicon master
yielding a negative imprint of 10 straight microchannels, 100 mm
deep/500 mm wide and then bonded to a glass slide. The device
was placed on an inverted Nikon TE2000-E (Nikon Instruments,
Japan) equipped with an Andor iXon-885 and a 406 long working
distance objective for the duration of the experiment. A bacterial
suspension (OD600 0.0025) was introduced into the microchannels
under continuous flow driven by a syringe pump (PHD Ultra,
Harvard Apparatus, MA, USA) at a flow rate of 0.5 ml/min for
18 hours. The biofilms were stained with Bacterial Viability Kit,
(Molecular Probes, Invitrogen Inc., Eugene, OR). Colistin, at a
final concentration of 20 mg/ml, was introduced into each channel
for 2 hours and one untreated channel served as a control. Phase
contrast, green and red fluorescence images were recorded for the
same field of view every 5 minutes. The cells absorbed propidium
iodide after cell death resulting from colistin exposure. Propidium
iodide resulted in fluorescence quenching of Syto 9, the green
fluorescent dye used to identify living cells. As cell death
progressed over time, there was a decrease in green fluorescence
due to a quenching effect and not a consequence of cell
detachment. The coverage of dead cells in the biofilm was
calculated in ImageJ [76] by adjusting the threshold of 8 bit binary
images and measuring the area coverage. This data was expressed
as a percentage of the total biofilm area (phase-contrast images) for
each time point. A Zeiss 510 confocal laser-scanning microscope
(CLSM) was used to acquire xyz optical section images before and
after colistin treatment of biofilms within the microfluidic device to
quantify the amount of biomass loss during treatment.
Supporting Information
Figure S1 Psl protects 24-hour biofilms from cationic
antimicrobial peptides.WT PAO1, WT PA14, DpslAB, DpelA,
DalgD, PBAD-psl, and CF127 biofilms were grown for 24, 48,
72 hours in microtiter plates. After a 2-hour treatment with
32 mg/ml of colistin (A) or polymyxin B (B), cell viability was
measure and reported at CFU (log10). Psl-mediated protection was
apparent for 24-hour biofilms, but dispensable at later time points.
(TIF)
Figure S2 Psl protects 24-hour biofilms from cationic
antimicrobial peptides. WT PAO1, WT PA14, DpslAB, DpelA,
DalgD, PBAD-psl, and CF127 biofilms were grown for 24, 48,
72 hours in microtiter plates. After a 2-hour treatment with
650 mg/ml of tobramycin (A) or 50 mg/ml ciprofloxacin (B), cell
viability was measure and reported at CFU (log10). Psl-mediated
protection was critical for DpslAB 24-hour biofilms treated with
tobramycin, but was not required at 48 or 72 hours. Tolerance to
ciprofloxacin in strains lacking Psl was not as apparent with this
assay.
(TIF)
Figure S3 A deletion of pslAB in the WT PAO1
background reduces total biomass in an in vitro biofilm
model. Crystal violet assays were used to quantify the total
biomass for air-liquid interface biofilms grown in 96 well plates for
24, 48, and 72-hour biofilms. The total biomass for DpslAB was
reduced relative to WT PAO1 for all time points measured.
Although PA14 does not produce Psl, a reduction in biomass was
not observed, presumably due to other contributing polymers in
the biofilm matrix. Deletions in pelA or DalgD did not reduce the
total biomass relative to WT PAO1. Both PBAD-psl and CF127 had
a greater than 2-fold increase in biomass for each time point
compared to WT PAO1.
(TIF)
Figure S4 Lectin staining reveals patterns of Psl distri-
bution in 24-hour biofilms. Fluorescently labeled HHA stained
Psl in WT PAO1, DpelA, DalgD, PBAD-psl, and CF127 biofilms [54].
Both PA14 and DpslAB lack Psl in the matrix and did not bind
HHA. Psl was distributed as a localized, fibrous material associated
withWT PAO1 and PBAD-psl biofilms, while inDpelA and DalgD, the
Psl matrix was uniformly distributed throughout the biofilm. HHA
localized to microcolonies in CF127 biofilms indicating that Psl was
enriched in these structures. Scale bars represent 10 mm.
(TIF)
Figure S5 Polymyxin B interaction with the extracellu-
lar matrix in planktonic cells. Images of over-producing Psl
(PBAD-psl) and Psl deficient (DpslAB) cells after a 2-hour challenge
with fluorescent polymyxin B. Polymyxin B accumulates in the
EPS of Psl over-expressing cells, but appears to bind directly to the
cell surface in the Psl deletion strain. Scale bars represent 10 mm.
(TIF)
Figure S6 Biofilms treated with water only did not
contribute to cell death in microfluidic channel. To serve
as a control, biofilms grown in microfluidic channels were treated
with sterile water only and monitored for cell death for 2 hours.
Images of WT PAO1 and mutant strain DpslAB stained with Syto
9 (live cells) and propidium iodide (dead cells) were acquired and
compared after 1 hour of treatment with water only.
(TIF)
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Figure S7 Biomass before and after treatment with
colistin. 3-D projection of confocal images of WT PAO1 and
mutant strain DpslAB were acquired and compared before (at
24 hours) and after treatment (at 26 hours) with 20 mg/ml colistin.
Cells were stained with Syto9 (Molecular Probes) and counted in
the series of xyz images. Scale bars represent 25 mm.
(TIF)
Figure S8 Psl increases MBC-B for E. coli and S. aureus.
MBC-B assay reveals an increase in tolerance toward colistin for
E. coli and PBAD-psl biofilms (A). Tolerance is also observed toward
tobramycin for S. aureus and PBAD-psl biofilms, but to a lesser extent
(B).
(TIF)
Text S1 Description of the strains and antibiotics used
in this study.
(DOCX)
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